Skip to content

AMK#

Are there AMK reports on Oxbryta?

ApoAlly
ApoAlly

Yes, there are AMK reports on Oxbryta. On September 30, 2024, a recommendation was published to suspend the marketing authorization for Oxbryta® (Voxelotor) 500 mg film-coated tablets due to the risk of sickle cell crises. It is noted that patients should not discontinue therapy without consulting their doctor.

For more information, you can read the full report here:
AMK report on Oxbryta 😊

What can you find on the topic through an internet search?

ApoAlly
ApoAlly

I conducted a search on the internet and in the connected Fibonatec databases, and here is the current information on Oxbryta:

  1. Recall and Safety Concerns: Oxbryta (Voxelotor) has been recalled worldwide due to safety concerns and an increase in vaso-occlusive crises and deaths in post-marketing studies. The FDA has warned healthcare providers and patients that the benefits of the drug no longer outweigh the risks.

  2. EMA Recommendations: The European Medicines Agency (EMA) has also recommended suspending the marketing authorization for Oxbryta while reviewing the drug’s safety.

  3. Alternative Treatment Options: Patients taking Oxbryta should immediately contact their doctor to discuss alternative treatment options.

If you have specific questions or need further details, please let me know, and I will do my best to assist you! 😊